{"filing":{"accession_number":"0001193125-26-258466","cik":"0001699382","ticker":"PMVP","company_name":"PMV Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"d94814d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526258466/d94814d8k.htm"},"events":[{"id":3667,"run_id":3216,"accession_number":"0001193125-26-258466","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure of shareholder vote results from PMV Pharmaceuticals' June 4, 2026 Annual Meeting. The filing reports voting outcomes on three proposals: election of Class III directors (David H. Mack and Laurie Stelzer), non-binding advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The detailed vote tallies (FOR, AGAINST, WITHHELD, ABSTAIN, BROKER NON-VOTE) are the hallmark of shareholder meeting result disclosures and are material to investors assessing governance and board composition.","company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","filing_date":"2026-06-05","items":[{"id":4665,"accession_number":"0001193125-26-258466","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from PMV Pharmaceuticals' June 4, 2026 Annual Meeting. The filing reports voting outcomes on three proposals: election of Class III directors (David H. Mack and Laurie Stelzer), non-binding advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The detailed vote tallies (FOR, AGAINST, WITHHELD, ABSTAIN, BROKER NON-VOTE) are the hallmark of shareholder meeting result disclosures and are material to investors assessing governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:50:04.345352+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4665,"accession_number":"0001193125-26-258466","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from PMV Pharmaceuticals' June 4, 2026 Annual Meeting. The filing reports voting outcomes on three proposals: election of Class III directors (David H. Mack and Laurie Stelzer), non-binding advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The detailed vote tallies (FOR, AGAINST, WITHHELD, ABSTAIN, BROKER NON-VOTE) are the hallmark of shareholder meeting result disclosures and are material to investors assessing governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:50:04.345352+00:00","company_name":"PMV Pharmaceuticals, Inc.","ticker":"PMVP","filing_date":"2026-06-05"}]}